首页> 美国卫生研究院文献>Case Reports in Medicine >Tophaceous Gout and Renal Insufficiency: A New Solution for an Old Therapeutic Dilemma
【2h】

Tophaceous Gout and Renal Insufficiency: A New Solution for an Old Therapeutic Dilemma

机译:痛风性痛风和肾功能不全:旧的治疗难题的新解决方案

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The prevalence of gout is increasing with increased life expectancy. Approximately half of the patients with gout have some degree of renal impairment. If both conditions persistently coexist, and in severe tophaceous gout, in particular, treatment has been difficult. We here report on the case of an 87-year-old woman, who had been suffering from recurrent gouty arthritis over 4 years. Monthly polyarthritis attacks were accompanied by subcutaneous tophi. Serum uric acid levels were constantly above 600 μmol/L (10 mg/dL). Allopurinol was no option because of intolerance, while benzbromarone was ineffective because of renal impairment. Therefore, the novel xanthin oxidase inhibitor febuxostat was started, achieving rapid control of serum urate levels (<360 μmol/L). After initial worsening of inflammation in the first weeks, gouty attacks stopped and all tophi resolved within the following 10 months. Renal function remained stable.
机译:痛风的患病率随着预期寿命的增加而增加。大约一半的痛风患者有一定程度的肾脏损害。如果这两种情况持续存在,特别是在严重的尖牙痛风中,治疗就很困难。我们在这里报告了一名87岁的女性的案例,该女性在4年内患有反复的痛风性关节炎。每月多关节炎发作伴有皮下痛风石。血清尿酸水平始终高于600µμmol / L(10µmg / dL)。别嘌呤醇由于不耐受而没有选择,而苯溴马隆由于肾功能不全而无效。因此,开始使用新型的黄嘌呤氧化酶抑制剂非布索坦,实现了对血清尿酸水平(<360 <μmol/ L)的快速控制。在最初的几周内炎症开始恶化后,痛风发作停止了,并且在随后的10个月内所有的痛风石消失了。肾功能保持稳定。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号